Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Toledo Data Fail To Give Galapagos A Lift

Underwhelming Results For Lead SIK Inhibitor

Executive Summary

Lead Toledo compound GLPG3970 has failed to live up to expectations in three clinical studies, setting Galapagos's pipeline plans back and causing further concern among the investment community.

You may also be interested in...



Ziritaxestat Failure Could Spell End For Gilead/Galapagos Pact

The Galapagos and Gilead partnership has had a tough few months and the failure of ziritaxestat, plus the decision not to develop filgotinib Stateside for rheumatoid arthritis, is calling into question the merits of the whole collaboration for the US biotech.

Galapagos Knocked By Knee Osteoarthritis Fail

Still reeling from the FDA rejection of its JAK inhibitor filgotinib for rheumatoid arthritis, the Belgium-headquartered biotech's ADAMTS-5 inhibitor developed with France's Servier is sunk after failing to significantly reduce cartilage loss compared with placebo in an OA trial.

Sanofi Goes All The Way In mRNA With Translate Bio Buy

Taking full control of partner Translate Bio means that Sanofi is the only big vaccine company with a wholly-owned mRNA platform in-house but observers say it is too early to declare that the Paris-headquartered group has bagged itself a bargain.

Topics

Related Companies

UsernamePublicRestriction

Register

SC144725

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel